Cargando…

Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial

PURPOSE: Mesenchymal stem/stromal cell therapy may reduce radiation-induced xerostomia. We investigated the long-term safety of autologous adipose tissue-derived mesenchymal stem/stromal cell (ASC) injections into the submandibular glands. EXPERIMENTAL DESIGN: An investigator-initiated, randomized,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynggaard, Charlotte Duch, Grønhøj, Christian, Jensen, Siri B., Christensen, Robin, Specht, Lena, Andersen, Elo, Andersen, Tobias T., Ciochon, Urszula M., Rathje, Gulla S., Hansen, Adam E., Stampe, Helene, Fischer-Nielsen, Anne, von Buchwald, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365378/
https://www.ncbi.nlm.nih.gov/pubmed/35486613
http://dx.doi.org/10.1158/1078-0432.CCR-21-4520
_version_ 1784765332202717184
author Lynggaard, Charlotte Duch
Grønhøj, Christian
Jensen, Siri B.
Christensen, Robin
Specht, Lena
Andersen, Elo
Andersen, Tobias T.
Ciochon, Urszula M.
Rathje, Gulla S.
Hansen, Adam E.
Stampe, Helene
Fischer-Nielsen, Anne
von Buchwald, Christian
author_facet Lynggaard, Charlotte Duch
Grønhøj, Christian
Jensen, Siri B.
Christensen, Robin
Specht, Lena
Andersen, Elo
Andersen, Tobias T.
Ciochon, Urszula M.
Rathje, Gulla S.
Hansen, Adam E.
Stampe, Helene
Fischer-Nielsen, Anne
von Buchwald, Christian
author_sort Lynggaard, Charlotte Duch
collection PubMed
description PURPOSE: Mesenchymal stem/stromal cell therapy may reduce radiation-induced xerostomia. We investigated the long-term safety of autologous adipose tissue-derived mesenchymal stem/stromal cell (ASC) injections into the submandibular glands. EXPERIMENTAL DESIGN: An investigator-initiated, randomized, single-center, placebo-controlled trial. Previous patients with oropharyngeal squamous cell carcinoma with radiation-induced xerostomia were randomly (1:1) allocated to receive a 2.8 million ASCs/cm(3) injection or placebo in both submandibular glands and followed for a minimum of 2 years. The primary endpoint was number of serious adverse events (SAE). Secondary endpoints included whole saliva flow rates and xerostomia-related symptoms. Data analysis was based on the intention-to-treat population using repeated measures mixed-effects linear models. RESULTS: Thirty-three patients were randomized; 30 patients were treated (ASC group, n = 15; placebo group, n = 15). Long-term safety data were collected from all 30 patients. During follow-up, 6 of 15 (40%) of the ASC-treated patients versus 5 of 15 (33%) of the placebo patients experienced an SAE; no SAEs appeared to be treatment related. Unstimulated whole saliva flow rate increased to 0.20 and 0.16 mL/minute in the ASC and placebo group, respectively, yielding a 0.05 mL/minute (95% confidence interval: 0.00–0.10; P = 0.051) difference between groups. Patient-reported xerostomia symptoms diminished according to a decreased xerostomia questionnaire summary score of 35.0 and 45.1, respectively [−10.1 (−18.1 to −2.2); P = 0.013]. Three of the visual analog scale xerostomia measures indicated clinical benefit following use of ASC. CONCLUSIONS: Our data show that ASC therapy is safe with a clinically relevant effect on xerostomia-related symptoms. Confirmation in larger randomized controlled trials is warranted.
format Online
Article
Text
id pubmed-9365378
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-93653782023-01-05 Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial Lynggaard, Charlotte Duch Grønhøj, Christian Jensen, Siri B. Christensen, Robin Specht, Lena Andersen, Elo Andersen, Tobias T. Ciochon, Urszula M. Rathje, Gulla S. Hansen, Adam E. Stampe, Helene Fischer-Nielsen, Anne von Buchwald, Christian Clin Cancer Res Translational Cancer Mechanisms and Therapy PURPOSE: Mesenchymal stem/stromal cell therapy may reduce radiation-induced xerostomia. We investigated the long-term safety of autologous adipose tissue-derived mesenchymal stem/stromal cell (ASC) injections into the submandibular glands. EXPERIMENTAL DESIGN: An investigator-initiated, randomized, single-center, placebo-controlled trial. Previous patients with oropharyngeal squamous cell carcinoma with radiation-induced xerostomia were randomly (1:1) allocated to receive a 2.8 million ASCs/cm(3) injection or placebo in both submandibular glands and followed for a minimum of 2 years. The primary endpoint was number of serious adverse events (SAE). Secondary endpoints included whole saliva flow rates and xerostomia-related symptoms. Data analysis was based on the intention-to-treat population using repeated measures mixed-effects linear models. RESULTS: Thirty-three patients were randomized; 30 patients were treated (ASC group, n = 15; placebo group, n = 15). Long-term safety data were collected from all 30 patients. During follow-up, 6 of 15 (40%) of the ASC-treated patients versus 5 of 15 (33%) of the placebo patients experienced an SAE; no SAEs appeared to be treatment related. Unstimulated whole saliva flow rate increased to 0.20 and 0.16 mL/minute in the ASC and placebo group, respectively, yielding a 0.05 mL/minute (95% confidence interval: 0.00–0.10; P = 0.051) difference between groups. Patient-reported xerostomia symptoms diminished according to a decreased xerostomia questionnaire summary score of 35.0 and 45.1, respectively [−10.1 (−18.1 to −2.2); P = 0.013]. Three of the visual analog scale xerostomia measures indicated clinical benefit following use of ASC. CONCLUSIONS: Our data show that ASC therapy is safe with a clinically relevant effect on xerostomia-related symptoms. Confirmation in larger randomized controlled trials is warranted. American Association for Cancer Research 2022-07-01 2022-04-29 /pmc/articles/PMC9365378/ /pubmed/35486613 http://dx.doi.org/10.1158/1078-0432.CCR-21-4520 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Translational Cancer Mechanisms and Therapy
Lynggaard, Charlotte Duch
Grønhøj, Christian
Jensen, Siri B.
Christensen, Robin
Specht, Lena
Andersen, Elo
Andersen, Tobias T.
Ciochon, Urszula M.
Rathje, Gulla S.
Hansen, Adam E.
Stampe, Helene
Fischer-Nielsen, Anne
von Buchwald, Christian
Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
title Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
title_full Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
title_fullStr Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
title_full_unstemmed Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
title_short Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
title_sort long-term safety of treatment with autologous mesenchymal stem cells in patients with radiation-induced xerostomia: primary results of the mesrix phase i/ii randomized trial
topic Translational Cancer Mechanisms and Therapy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365378/
https://www.ncbi.nlm.nih.gov/pubmed/35486613
http://dx.doi.org/10.1158/1078-0432.CCR-21-4520
work_keys_str_mv AT lynggaardcharlotteduch longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT grønhøjchristian longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT jensensirib longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT christensenrobin longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT spechtlena longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT andersenelo longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT andersentobiast longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT ciochonurszulam longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT rathjegullas longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT hansenadame longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT stampehelene longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT fischernielsenanne longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial
AT vonbuchwaldchristian longtermsafetyoftreatmentwithautologousmesenchymalstemcellsinpatientswithradiationinducedxerostomiaprimaryresultsofthemesrixphaseiiirandomizedtrial